Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas

Copanlisib, an intravenously administered agent with inhibitory activity that predominantly targets the alpha and delta isoforms of phosphoinositol 3-kinase, was granted accelerated approval by the United States Food and Drug Administration on the basis of its activity in the third-line treatment of...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Clin Lymphoma Myeloma Leuk
मुख्य लेखकों: Cheson, Bruce D., O’Brien, Susan, Ewer, Michael S., Goncalves, Marcus D., Farooki, Azeez, Lenz, Georg, Yu, Anthony, Fisher, Richard I., Zinzani, Pierre L., Dreyling, Martin
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2018
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC6642803/
https://ncbi.nlm.nih.gov/pubmed/30584024
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2018.11.021
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन